Goldman Scrutinizes Hits, Misses, And Growth Trajectory Concerns For Eli Lilly And Its Its Obesity and Diabetes Drugs
Eli Lilly boosts production for obesity and diabetes drugs, reports mixed Q1 results. Expectations for supply growth in 2024 outlined. Insights into payor access and reimbursement strategies discussed.